[6-K] Clearmind Medicine Inc. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Clearmind Medicine (CMND) furnished a Form 6-K that attaches a press release titled “Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder.” The filing also states that the first four paragraphs of this press release are incorporated by reference into the company’s effective registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), becoming part of those filings to the extent not later superseded.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: October 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on October 30, 2025, titled “Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder”.

The first four paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: October 30, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

FAQ

What did CMND file in this update?

CMND furnished a Form 6-K that includes a press release as Exhibit 99.1.

What is the topic of the attached press release for CMND?

It is titled “Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder.”

Which CMND registration statements incorporate the press release content?

The first four paragraphs are incorporated by reference into Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).

How much of the press release is incorporated by reference for CMND?

The first four paragraphs are incorporated by reference.

When does the incorporation by reference become effective for CMND?

They become part of the registration statements from the date this report is submitted, to the extent not superseded by later filings.

Where can investors find the CMND press release in the filing?

It appears as Exhibit 99.1 to the Form 6-K.